Hunter Associates Investment Management LLC Has $2.02 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Hunter Associates Investment Management LLC lowered its position in Hologic, Inc. (NASDAQ:HOLX) by 2.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 27,905 shares of the medical equipment provider’s stock after selling 649 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Hologic were worth $2,017,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of HOLX. Wolff Wiese Magana LLC bought a new stake in Hologic in the 3rd quarter valued at $25,000. General Partner Inc. acquired a new stake in shares of Hologic during the 4th quarter worth about $26,000. First Horizon Advisors Inc. boosted its holdings in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the period. Sunbelt Securities Inc. acquired a new position in Hologic in the 2nd quarter valued at about $37,000. Finally, Cromwell Holdings LLC raised its holdings in Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 416 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 1.1 %

Shares of NASDAQ HOLX opened at $72.17 on Friday. The company has a market cap of $16.29 billion, a price-to-earnings ratio of 21.67, a PEG ratio of 2.33 and a beta of 0.97. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 12 month low of $68.61 and a 12 month high of $84.67. The stock has a 50-day moving average price of $73.49 and a two-hundred day moving average price of $78.11.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.89 EPS. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.88% of the stock is currently owned by company insiders.

Analyst Ratings Changes

HOLX has been the topic of several research reports. Mizuho decreased their target price on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Jefferies Financial Group assumed coverage on Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective on the stock. Wolfe Research initiated coverage on shares of Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. UBS Group lifted their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Leerink Partners decreased their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Seven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $88.92.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.